Treprostinil Palmitil Inhalation Powder
Sponsors
Insmed Inc., Insmed Incorporated
Conditions
Healthy VolunteersHepatic ImpairmentInterstitial Lung DiseaseProgressive Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease
Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
CompletedNCT06091579
Start: 2020-09-17End: 2021-01-12Updated: 2023-10-19
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
RecruitingNCT07643155
Start: 2026-07-14End: 2027-02-07Target: 30Updated: 2026-09-11
Phase 2
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
CompletedNCT05649722
Start: 2023-05-11End: 2026-04-01Updated: 2026-04-23
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Active, not recruitingCTIS2023-505540-19-00
Start: 2023-04-24Target: 27Updated: 2025-02-27
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
CompletedCTIS2023-505541-99-00
Start: 2022-06-28End: 2025-03-05Target: 23Updated: 2025-04-02
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
RecruitingCTIS2023-505539-11-00
Start: 2023-04-06Target: 23Updated: 2025-11-03
Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingNCT07179380
Start: 2026-01-07End: 2028-12-30Target: 344Updated: 2026-08-14
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingNCT07234032
Start: 2026-07-20End: 2031-01-22Target: 344Updated: 2026-08-13
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Not yet recruitingCTIS2025-521558-40-00
Target: 73Updated: 2026-01-27
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
RecruitingNCT07481981
Start: 2026-07-21End: 2029-01-28Target: 344Updated: 2026-09-16
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Not yet recruitingCTIS2025-521769-29-00
Target: 96Updated: 2026-07-01
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
Not yet recruitingNCT07805785
Start: 2026-12-01End: 2030-08-31Target: 800Updated: 2026-09-04